Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia

Hemoglobin

Volumn 39, Issue 5, 2015, Pages 327-329

  Karimi, Mehran ^a   Arandi, Nargess ^a   Haghpanah, Sezaneh ^a   Ansari, Shahla ^b   Azarkeyvan, Azita ^c   Bordbar, Mohammadreza ^a   Safaei, Sanaz ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

Author keywords

chelation therapy; deferasirox (Exjade or DFX); serum ferritin; Thalassemia intermedia ( TI)

Indexed keywords

DEFERASIROX; FERRITIN; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; BETA THALASSEMIA; BETA THALASSEMIA INTERMEDIA; CHELATION THERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON OVERLOAD; MALE; MULTICENTER STUDY; QUASI EXPERIMENTAL STUDY; SPLENECTOMY; THALASSEMIA INTERMEDIA; ADOLESCENT; BLOOD; COMPLICATION; METABOLISM; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BENZOATES; BETA-THALASSEMIA; CHILD; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 84940777226     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2015.1057735     Document Type: Article

References (11)

1. Maakaron JE, Taher AT. Complications and management of thalassemia intermedia. J Appl Hematol. 2012;3(4):143-146.
2. Musallam KM, Cappellini MD, Taher AT. Iron overload in β-thalassemia intermedia: An emerging concern. Curr Opin Hematol. 2013;20(3):187-192.
3. Musallam KM, Taher AT, Rachmilewitz EA. β-Thalassemia intermedia: A clinical perspective. Cold Spring Harb Perspect Med. 2012;2(7):a013482. doi: 10.1101/cshperspect.a013482.
4. Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of b thalassaemia intermedia. Br J Haematol. 2011;152(5):512-523.
5. Taher A, Musallam KM, El Rassi F, et al. Levels of non transferrin bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol. 2009;146(5):569-572.
6. Taher A, Hershko C, Cappellini MD. Iron overload in thalassaemia intermedia: Reassessment of iron chelation strategies. Br J Haematol. 2009;147(5):634-640.
7. Taher AT, Porter J, Viprakasit V, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 2012;120(5):970-977.
8. Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: The OPTIMAL CARE study. Blood. 2010;115(10):1886-1892.
9. Kwiatkowski JL. Real-world use of iron chelators. Hematology Am Soc Hematol Edu Program. 2011;2011:451-458.
10. Taher AT, Musallam KM, Karimi M, et al. Contemporary approaches to treatment of β-thalassemia intermedia. Blood Rev. 2012;26(1):S24-S27.
11. Maakaron J, Cappellini M, Taher A. An update on thalassemia intermedia. J Med Liban. 2013;61(3):175-182.